Skip to main content
Matthew Drake, MD, Endocrinology, Rochester, MN, Mayo Clinic Hospital - Rochester


Endocrinology Rochester, MN

Diabetes, Osteoporosis & Bone Metabolism Medicine, Parathyroid, Thyroid

Associate Professor of Medicine at Mayo Medical School

Dr. Drake is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Drake's full profile

Already have an account?

Education & Training

  • Duke University Hospital
    Duke University HospitalFellowship, Endocrinology, Diabetes, and Metabolism, 2003 - 2005
  • Duke University Hospital
    Duke University HospitalResidency, Internal Medicine, 2001 - 2003
  • Washington University in St. Louis School of Medicine
    Washington University in St. Louis School of MedicineClass of 2001
  • Harvard University
    Harvard UniversityA.B., Biology, Magna Cum Laude, 1989 - 1993

Certifications & Licensure

  • MN State Medical License
    MN State Medical License 2006 - 2024
  • NC State Medical License
    NC State Medical License 2001 - 2006
  • American Board of Internal Medicine Endocrinology, Diabetes and Metabolism

Awards, Honors, & Recognition

  • New Investigator Award, Department of Medicine Mayo Clinic, Rochester, MN, 2010
  • Young Investigator Award American Society for Bone and Mineral Research, 2009
  • Summa Cum Laude Thesis Harvard College, 1993
  • Join now to see all

Publications & Presentations


Journal Articles

  • Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma  
    Inwards DJ, Fishkin PA, LaPlant BR, Drake MT, Kurtin PJ, Nikcevich DA, Wender DB, Lair BS, Witzig TE, Ann Oncol, 7/1/2014
  • Effects of suppression of follicle-stimulating hormone secretion on bone resorption markers in postmenopausal women  
    Drake MT, McCready LK, Hoey KA, Atkinson EJ, Khosla S, Obstet Gynecol Surv, 5/1/2011
  • Corrigendum to "Circulating osteogenic cells: Characterization and relationship to rates of bone loss in postmenopausal women"  
    Undale A, Srinivasan B, Drake M, McCready L, Atkinson E, Peterson J, Riggs BL, Amin S, Modder UI, Khosla S, Bone, 1/1/2011
  • Join now to see all

Books/Book Chapters


  • Controversies in Pharmaceutical Management of Osteoporosis Therapy
    Drake MT, American Association of Clinical Endocrinologists Annual Meeting, 5/1/2014
  • Skeletal Structural Changes and Fracture Risk in Monoclonal Gammopathy of Undetermined Significance.
    Drake MT, Central Society for Clinical and Translational Research Annual Meeting, Chicago, IL, 4/1/2014
  • Monoclonal Gammopathy Associated Bone Loss
    Drake MT, Dresden University Medical Center, Dresden, Germany, 4/1/2014
  • Join now to see all


  • Monoclonal Gammopathy of Undetermined Significance (MGUS): Indications for Pre-Diagnostic Testing, Subsequent Diagnoses, and Follow-up Practice 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Optimizing Bone Health in Multiple Myeloma. 
    Atlanta, GA - 5/1/2014
  • Monoclonal gammopathy-associated bone loss. 
  • Join now to see all

Press Mentions

  • Antihypertensive Medication Use in Older Adults at Risk for Hip Fracture—Reply
    Antihypertensive Medication Use in Older Adults at Risk for Hip Fracture—ReplyOctober 22nd, 2019
  • Side Effects of Bisphosphonates for Osteoporosis
    Side Effects of Bisphosphonates for OsteoporosisMay 29th, 2019
  • Vitamin D: Not Just the Sunshine Vitamin Anymore
    Vitamin D: Not Just the Sunshine Vitamin AnymoreApril 12th, 2019
  • Join now to see all

Grant Support

  • Pathogenesis Of Monoclonal Gammopathy Bone DiseaseNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2010–2011

Professional Memberships

Hospital Affiliations